$24.81 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter
Wall Street analysts expect that Nektar Therapeutics (NASDAQ:NKTR) will report $24.81 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest sales estimate coming in at $20.08 million and the highest estimate coming in at $35.50 million. Nektar Therapeutics reported sales of $152.93 million during the same quarter last year, which indicates a negative year-over-year growth rate of 83.8%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 6th.
On average, analysts expect that Nektar Therapeutics will report full year sales of $1.17 billion for the current fiscal year, with estimates ranging from $1.12 billion to $1.20 billion. For the next financial year, analysts forecast that the company will post sales of $457.12 million per share, with estimates ranging from $135.00 million to $1.18 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.22 by $0.11. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the previous year, the firm posted ($0.39) EPS. The business’s revenue for the quarter was up 3043.7% compared to the same quarter last year.
NASDAQ:NKTR opened at $59.00 on Friday. Nektar Therapeutics has a 12-month low of $21.75 and a 12-month high of $111.36. The company has a market cap of $10.08 billion, a P/E ratio of -107.27 and a beta of 2.27. The company has a quick ratio of 19.55, a current ratio of 19.67 and a debt-to-equity ratio of 0.13.
In other Nektar Therapeutics news, Director Jeffrey Robert Ajer sold 6,750 shares of the business’s stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $56.76, for a total transaction of $383,130.00. Following the completion of the transaction, the director now owns 15,750 shares in the company, valued at approximately $893,970. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Howard W. Robin sold 43,334 shares of the business’s stock in a transaction on Monday, June 25th. The stock was sold at an average price of $51.82, for a total value of $2,245,567.88. Following the transaction, the chief executive officer now owns 267,690 shares of the company’s stock, valued at approximately $13,871,695.80. The disclosure for this sale can be found here. Insiders have sold a total of 269,334 shares of company stock valued at $14,508,848 in the last quarter. 4.31% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in NKTR. HRT Financial LLC acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at $421,000. Advisors Asset Management Inc. acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at $373,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at $3,130,000. HighPoint Advisor Group LLC lifted its holdings in shares of Nektar Therapeutics by 66.4% in the second quarter. HighPoint Advisor Group LLC now owns 11,335 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 4,522 shares during the period. Finally, WINTON GROUP Ltd lifted its holdings in shares of Nektar Therapeutics by 41.1% in the second quarter. WINTON GROUP Ltd now owns 7,685 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 2,238 shares during the period. Institutional investors own 92.21% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Featured Story: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.